Obesity Medication Now Covered for Medicare Patients: Here's What You Need to Know
For the first time ever, Medicare is covering the cost of obesity medications for older Americans. A co-payment of just $50 per month will be required for GLP-1s, a class of drugs used to treat obesity. This is a significant step forward in improving access to these medications for individuals over the age of 65.
A New Step in Medicare Coverage
While prescription drug plans under Medicare Part D have been covering some GLP-1s for conditions such as diabetes and cardiovascular disease, federal law has prohibited coverage specifically for obesity. This is about to change with the introduction of Medicare's new Bridge demonstration program, which will temporarily cover these drugs for more beneficiaries, particularly those who are overweight and have prediabetes or uncontrolled hypertension.
With more than 69 million beneficiaries enrolled in Medicare, it is expected that several million will access these drugs through the Bridge program. Roughly 15 million to 20 million elderly Medicare beneficiaries could potentially qualify for weight loss drugs.
Navigating Potential Challenges
However, the rollout might not go without a hitch. Healthcare providers will need to submit prior authorization requests to confirm that patients meet the eligibility criteria. Some physicians have expressed concerns that this process could be burdensome. Additionally, there are worries that the new coverage could lead to a significant increase in demand, which might overwhelm clinics and pharmacies. There is also a lack of public awareness about the program.
Another point of contention is the temporary nature of the Bridge program. Unless the program is extended or replaced, coverage for obesity drugs will expire at the end of 2027. Permanent coverage would need federal law changes or agreement among private health insurers to provide the medications in Part D plans. This creates uncertainty for patients who may begin treatments that experts view as lifelong therapies.
Understanding the Savings for Patients
The $50 monthly co-payment is considerably less than what uninsured patients usually pay for obesity drugs. This price is consistent across all dosages, unlike for out-of-pocket payers where the cost increases with the dosage. However, the $50 monthly copay for GLP-1s will not be counted towards a patient's Part D deductible or the $2,100 annual cap on prescription drug costs.
Who is Eligible and How Does It Work?
The Bridge program functions differently from traditional Medicare drug coverage. It is available to Medicare beneficiaries with Part D coverage, but the cost is covered by taxpayer dollars and beneficiary copays rather than private insurers. A healthcare provider must determine a person's eligibility based on their body weight and health status.
Eligible patients are those with a body mass index (BMI) of 35 or higher. Additionally, individuals with lower BMIs who have at least one related condition, such as prediabetes, a previous heart attack or stroke, or blocked arteries in their arms or legs, can also qualify.
Looking to the Future
The introduction of this new coverage could open up a vast patient population for drug manufacturers, leading to increased competition in the obesity market. However, there is still uncertainty about what will happen when the Bridge program expires at the end of 2027. This raises questions about whether beneficiaries who start treatment will be able to continue it long term.
A permanent solution could be the passage of a bill called the Treat and Reduce Obesity Act, which would lift Medicare's long-standing ban on coverage of obesity drugs. Despite bipartisan support, concerns about cost have slowed the legislation. However, proponents argue that the estimate may overstate the net cost because it does not fully capture potential savings from preventing obesity-related conditions.
For the first time ever, Medicare is covering the cost of obesity medications for older Americans. A co-payment of just $50 per month will be required for GLP-1s, a class of drugs used to treat obesity. This is a significant step forward in improving access to these medications for individuals over the age of 65.
A New Step in Medicare Coverage
While prescription drug plans under Medicare Part D have been covering some GLP-1s for conditions such as diabetes and cardiovascular disease, federal law has prohibited coverage specifically for obesity. This is about to change with the introduction of Medicare's new Bridge demonstration program, which will temporarily cover these drugs for more beneficiaries, particularly those who are overweight and have prediabetes or uncontrolled hypertension.
With more than 69 million beneficiaries enrolled in Medicare, it is expected that several million will access these drugs through the Bridge program. Roughly 15 million to 20 million elderly Medicare beneficiaries could potentially qualify for weight loss drugs.
Navigating Potential Challenges
However, the rollout might not go without a hitch. Healthcare providers will need to submit prior authorization requests to confirm that patients meet the eligibility criteria. Some physicians have expressed concerns that this process could be burdensome. Additionally, there are worries that the new coverage could lead to a significant increase in demand, which might overwhelm clinics and pharmacies. There is also a lack of public awareness about the program.
Another point of contention is the temporary nature of the Bridge program. Unless the program is extended or replaced, coverage for obesity drugs will expire at the end of 2027. Permanent coverage would need federal law changes or agreement among private health insurers to provide the medications in Part D plans. This creates uncertainty for patients who may begin treatments that experts view as lifelong therapies.
Understanding the Savings for Patients
The $50 monthly co-payment is considerably less than what uninsured patients usually pay for obesity drugs. This price is consistent across all dosages, unlike for out-of-pocket payers where the cost increases with the dosage. However, the $50 monthly copay for GLP-1s will not be counted towards a patient's Part D deductible or the $2,100 annual cap on prescription drug costs.
Who is Eligible and How Does It Work?
The Bridge program functions differently from traditional Medicare drug coverage. It is available to Medicare beneficiaries with Part D coverage, but the cost is covered by taxpayer dollars and beneficiary copays rather than private insurers. A healthcare provider must determine a person's eligibility based on their body weight and health status.
Eligible patients are those with a body mass index (BMI) of 35 or higher. Additionally, individuals with lower BMIs who have at least one related condition, such as prediabetes, a previous heart attack or stroke, or blocked arteries in their arms or legs, can also qualify.
Looking to the Future
The introduction of this new coverage could open up a vast patient population for drug manufacturers, leading to increased competition in the obesity market. However, there is still uncertainty about what will happen when the Bridge program expires at the end of 2027. This raises questions about whether beneficiaries who start treatment will be able to continue it long term.
A permanent solution could be the passage of a bill called the Treat and Reduce Obesity Act, which would lift Medicare's long-standing ban on coverage of obesity drugs. Despite bipartisan support, concerns about cost have slowed the legislation. However, proponents argue that the estimate may overstate the net cost because it does not fully capture potential savings from preventing obesity-related conditions.